Valneva SE American Depositary Shares

Valneva SE reported Q1 2026 financial results with total product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from a successful reserved offering completed in April 2026. The company announced participation in U.S. and European investor conferences in June 2026.

Valneva SE reported its share capital composition as of May 31, 2026, with 189.77 million ordinary shares and double voting rights on 1,859 shares. The company also announced Q1 2026 financial results showing product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from an April reserved of...

Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and older in Phase 3 VALOR trial. The vaccine candidate was well-tolerated.

Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in people aged five years and older during Phase 3 VALOR trial. The companies also announced Valneva's participation in the 26th World Vaccine Congress in Washington DC.

Pomerantz LLP is investigating potential securities fraud claims against Valneva SE and partner Pfizer following the failure of their Phase 3 Lyme disease vaccine candidate (LB6V) to meet its primary endpoint. The announcement triggered a sharp 37.11% decline in Valneva's ADR price on March 23, 2026.